Cerebrolysin plus antipsychotics in childhood autism: 180-day observation
M. G. Radzivil, V. M. Bashina · 2006 · Zh Nevrol Psikhiatr Im S S Korsakova. 2006;106(2):21–25. PMID 16548370.
Reported findings and study design
Open prospective series followed for 180 days. All participants received both Cerebrolysin and typical antipsychotics.
Dose, route and schedule
Two courses of 15 intramuscular injections of 1.0 mL each, given every other day, with a two-month interval between courses. Typical antipsychotics continued at age-adjusted doses.
Protocol source ↗ · Original indexed abstract
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| CARS score | 37.7 at baseline to 32.6 at day 180 | p < 0.001 versus baseline |
| Rated substantially improved | 38% after the first course, more than 50% after the second, and 71% at day 180 | |
| Selected developmental age-equivalent changes | Self-care +0.3 years; receptive and expressive speech +0.2 years; fine motor function +0.1 years | |
| Clinical deterioration | None reported. The abstract does not give adverse-event counts. |
All changes occurred during combined treatment. The study cannot isolate the effect of Cerebrolysin.
Source for these results ↗ · Reviewed 2026-11-10
For research and education. Consult a qualified clinician for medical advice.
Study limitations and source details
Study limitations
- There was no Cerebrolysin-only, placebo, or antipsychotic-only arm in the indexed report.
- The reported absence of clinical deterioration does not establish that adverse events were systematically collected or absent.
Source access
Original indexed abstract checked for the regimen, 180-day follow-up and outcome values. Full text was not located.
Source reviewed 2026-11-10.
Source type: Original clinical journal article
Citation and original source
Original source: M. G. Radzivil, V. M. Bashina. Cerebrolysin plus antipsychotics in childhood autism: 180-day observation Zh Nevrol Psikhiatr Im S S Korsakova. 2006;106(2):21–25. PMID 16548370. 2006.
Molekul research summary: https://molekul.io/research/cerebrolysin-radzivil-autism-2006. Cite the original publication for its findings and this page when referring to Molekul’s summary or evidence appraisal.
Bibliography entry